PharmSync
ActiveSummary
PharmSync has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €104,589 and a net result of €57,846. Its solvency ranks better than 79% of 13,646 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
- Equity
- €104,589
- Profit
- €57,846
- KURDI AmmarDirector
Why 92raises riskFounded in 2023Last filed accounts filed 31 days late; 1 of the last 3 latelowers riskLiquidity: current ratio 4.25, cash €117,092Equity €104,589 (76.5% of total assets)Show the evidence
Checked score
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro): better than 90% on solvency, 90% on liquidity, 95% on profitability and 95% on growth.
The bankruptcy probability was computed on 28-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
This company filed its last 2 accounts on average 15 days after the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
- Annual accounts filedfinancial year 2025 · micro…
- Equity above €100,000equity €104,589 ▲124%
- Annual accounts filedfinancial year 2024 · micro…
Financials · financial year 2025, micro format
2025 annual accounts filed late (31 days) Filed on 31 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00467955.
Source amounts without an identifiable currency are assumed to be EUR.
2024 to 2025, 2 financial years
The operating result rises in 2025; 2025 is 30% above 2024.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Peer companies
Historical observationOf the 39,278 companies that looked in July 2024 the way this one looks now, 1.8% went bankrupt within 24 months and 95.8% are still going.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
A further 0.1% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.3% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 39,278 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Other operating charges640/8 | €118 | €386 | ▲ 227% |
| Gross operating margin9900 | €57,723 | €75,547 | ▲ 30.9% |
| Operating profit (loss)9901 | €57,605 | €75,161 | ▲ 30.5% |
| Financial income75/76B | €0 | €85 | ▲ 2,842× |
| Recurring financial income75 | €0 | €85 | ▲ 2,842× |
| Financial charges65/66B | €1,073 | €1,478 | ▲ 37.8% |
| Recurring financial charges65 | €1,073 | €1,478 | ▲ 37.8% |
| Profit (loss) for the period before taxes9903 | €56,532 | €73,768 | ▲ 30.5% |
| Income taxes67/77 | €12,789 | €15,922 | ▲ 24.5% |
| Profit (loss) for the period9904 | €43,743 | €57,846 | ▲ 32.2% |
| Profit (loss) for the period to be appropriated9905 | €43,743 | €57,846 | ▲ 32.2% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €57,767 | €136,689 | ▲ 137% |
| Fixed assets21/28 | €400 | €400 | = |
| Financial fixed assets28 | €400 | €400 | = |
| Current assets29/58 | €57,367 | €136,289 | ▲ 138% |
| Amounts receivable within one year40/41 | €2,239 | €19,046 | ▲ 751% |
| Trade receivables40 | €2,113 | €18,920 | ▲ 795% |
| Other amounts receivable41 | €126 | €126 | = |
| Cash at bank and in hand54/58 | €54,668 | €117,092 | ▲ 114% |
| Deferred charges and accrued income490/1 | €460 | €152 | ▼ 67.1% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €57,767 | €136,689 | ▲ 137% |
| Equity10/15 | €46,743 | €104,589 | ▲ 124% |
| Contributions10/11 | €3,000 | €3,000 | = |
| Profit (loss) carried forward14 | €43,743 | €101,589 | ▲ 132% |
| Amounts payable17/49 | €11,024 | €32,100 | ▲ 191% |
| Amounts payable within one year42/48 | €11,024 | €32,100 | ▲ 191% |
| Trade debts44 | €963 | €22,715 | ▲ 24× |
| Suppliers440/4 | €963 | €22,715 | ▲ 24× |
| Taxes, remuneration and social security45 | €9,877 | €9,221 | ▼ 6.6% |
| Taxes450/3 | €9,877 | €9,221 | ▼ 6.6% |
| Other amounts payable47/48 | €184 | €164 | ▼ 10.9% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | €43,743 | €57,846 | ▲ 32.2% |
| Operating cash flow (approximation) | €43,743 | €57,846 | ▲ 32.2% |
| Investment in fixed assets (approximation) | - | €0 | - |
| Change in cash | - | €62,424 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (2)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | micro format | 31-08-2026 | 2026-00467955 |
| 31-12-2024 | micro format | 29-07-2025 | 2025-00321051 |
Similar companies · same sector, comparable size
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Mandate history
- Board
| Name | Functions and periods |
|---|---|
| KURDI Ammar |
|
Owners and capital
Capital and shareholders
- KURDI Ammar 92 shares (92%) · €2,760
- SADEK Rim 8 shares (8%) · €240
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.
- 18-12-2023 Incorporation · €3,000 · 100 shares
Group and network
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.
History
Acts, filings and financial milestones
18-12
Gazette deed
IncorporationAppointment: KURDI Ammar (director) · Founder · Power of attorney16 facts ▸
- Founder, KURDI Ammar
- Founder, SADEK Rim
- Power of attorney, LEYS Nele Lieve
- Incorporation, 12-12-2023
- Founding capital, €3,000
- Other provision, 01-12-2023
- Capital contribution, €2,760
- Capital contribution, €240
- Bank account, 3000, “vennootschap in oprichting” (deed in Dutch)
- Declaration, “bevestiging deponering overeenkomstig Wetboek van vennootschappen en verenigingen”, EUR (deed in Dutch)
- Director appointment, KURDI Ammar (director)
- Registered office clause, “2610 Antwerpen (Wilrijk), Paviljoenlaan 10, bus 7” (deed in Dutch)
- +4 further facts in this act
Register details
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 28 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
1 establishment unit
1 parcel
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 11463D0447/00P000 | Flanders | 674 m² | 1 · 240 m² | 17.2 m · 5 |
How the parcels are linked
Articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “De uitbating, huur en verhuur van één of meer apotheken; Het verzorgen van vervangingen in of voor één of meer apotheken; Groothandel, aan-…” (deed in Dutch)
15 activities (deed in Dutch)
- De uitbating, huur en verhuur van één of meer apotheken;
- Het verzorgen van vervangingen in of voor één of meer apotheken;
- Groothandel, aan- en verkoop, bereiding van alle soorten scheikundige, farmaceutische, para farmaceutische, phytofarmaceutische en homeopatische producten, veeartsenij- en drogisterijproducten, specialiteiten, cosmetica en hygiënische producten, waaronder begrepen zijn de parfumerie, dieetproducten, natuurvoeding en dergelijke;
- Aan- en verkoop en herstellingen van alle gezichts- en gehoorapparaten en aanverwante artikelen;
- Aan- en verkoop en de handel in alle soorten materialen en voorwerpen van bandagisten en orthopedisten;
- Handel in alle soorten toebehoren met betrekking tot de uitbating en de gezondheidszorg in het algemeen;
- Het uitvoeren van analyses;
- Klinisch biologisch onderzoek;
- Het verlenen van voedings- en dieetadvies;
- Consultancy met betrekking tot de scheikundige, farmaceutische, de para farmaceutische en de phytofarmaceutische sector;
- Gelaatsverzorging en schoonheidsactiviteiten;
- Investeringsactiviteiten in aandelen, cryptocurrency en vastgoed;
- Het aanhouden van participaties in andere vennootschappen;
- Het nemen van mandaten zowel als bestuurders, als vereffenaar of enig ander mandaat, het investeren in roerende -, onroerende goederen en financiële instrumenten en dit zowel met eigen als met vreemde middelen;
- Consultancy opdrachten in verschillende domeinen.
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- PharmSync
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- One provision in the deed
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Met of zonder beperking van duur, bij bezoldigd mandaat bepaalt algemene vergadering met absolute meerderheid of enige aandeelhouder bedrag…” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Last Friday of June at 18:00
Oversight and winding up
- Statutory auditorA statutory auditor is a registered auditor who checks the accounts; small companies need not have one. According to the deed, the legal criteria do not require one here.
- No statutory auditor
- Dissolution ruleWhen and by whom the company can be dissolved.
- One provision in the deed